Clinical trials: Syndrome
Acute Coronary Syndrome
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard…
- Trial name
- NCT00852397
- Testing
- Apixaban
- Where
- 18 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes, Anemia
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00695396
- Testing
- Epoetin alfa
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.
- Trial name
- B4Z-US-050 (NCT00418262)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Oklahoma
Sleep Disordered Breathing, Congestion, Nasal
To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Resistance During Sleep, Promoting Nasal Route Breathing and Reducing the Signs and Symptoms of Sleep Disordered Breathing in a Group of Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep.
To characterize the performance of the nasal dilator strip in lowering nasal resistance during sleep, promoting nasal route breathing and reducing the signs and symptoms of sleep disordered breathing in a group of chronic…
- Trial name
- NCT03105297
- Testing
- Prototype nasal dilator strip, No strip
- Where
- Australia
- Volunteers
- 91 people
- Sponsor
- GlaxoSmithKline
Transient Ischemic Attack, Stroke
Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
The goal of this study is to develop a novel study design to safely and ethically conduct a long-term randomized controlled trial among patients at high risk for both sleep apnea and cardiovascular events that will examine…
- Trial name
- SleepTight (NCT01446913)
- Testing
- Standard CPAP Intervention, Enhanced CPAP Intervention
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Yale University
Septic Shock
Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock
There is a knowledge gap regarding the optimal initial fluid to achieve effective resuscitation and improved outcomes in septic shock.
- Trial name
- NCT03366220
- Testing
- Plasma, Balanced crystalloids
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV Infection
Fish Oil for HIV-Related Inflamm-aging and Immune Senescence
HIV infection is associated with premature aging of the immune system. It is believe that the persistent inflammation that accompanies HIV infection is a major contributor to premature immune aging.
- Trial name
- NCT02102724
- Testing
- Fish oil that contains omega-3 fatty acids
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rush University Medical Center
Tourette Syndrome
Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tics are the core symptom of Tourette syndrome. These are repetitive, sudden, semi-voluntary movements or sounds. In some children, these tics can be especially bad and require treatment, however, options are limited.
- Trial name
- TICS (NCT02356003)
- Testing
- Low frequency repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Calgary
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3…
- Trial name
- NCT00571961
- Testing
- Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
Hereditary Angioedema
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
The purpose of this study was to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsen on the quality and pattern of HAE attacks and their impact on quality of life (QoL).
- Trial name
- NCT05139810
- Testing
- Donidalorsen
- Where
- 51 sites in United States, Belgium and 12 more
- Volunteers
- 91 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone, when given together with sorafenib and to see how well they…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT02728050
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Washington
Behcet's Disease
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1.
- Trial name
- NCT01960790
- Volunteers
- 473 people
- Sponsor
- AbbVie
Complex Regional Pain Syndromes, Back Pain
Virtual Reality Guided Imagery for Chronic Pain
To assess treatment with an at-home Virtual Reality Guided Imagery (VR-GI) intervention, 36 patients with chronic pain (18 with chronic back pain, CBP, and 18 with complex regional pain syndrome, CRPS) will complete a 2-week…
- Trial name
- VRGI (NCT04849897)
- Testing
- Experimental: Virtual Reality Guided Imagery, Active Comparator: Audio Only Guided Imagery
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
HIV Infections
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients.
- Trial name
- NCT00144170
- Testing
- Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- Where
- 174 sites in Argentina, Austria and 15 more
- Volunteers
- 882 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
Neurofibromatosis Type 1, Precancerous Condition
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a…
- Trial name
- NCT00060008
- Testing
- fludeoxyglucose F 18, gadopentetate dimeglumine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital of Philadelphia
Muscle Weakness
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome.
- Trial name
- 3-4DAP (NCT02090725)
- Testing
- 3-4 Diaminopyridine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jeffrey A. Cohen, MD
HIV Infections
A Peer-Driven Intervention to Increase PrEP Uptake Among Minority MSM
The objective of this study is to develop an effective peer-driven intervention (PDI) approach and assess its feasibility and efficacy on pre-exposure prophylaxis (PrEP) uptake among men who have sex with men.
- Trial name
- NCT05161663
- Testing
- Peer-driven intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
22Q11.2 Deletion Syndrome
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to <18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).
- Trial name
- INSPIRE (NCT05149898)
- Testing
- ZYN002
- Where
- 3 sites in United States, Australia
- Volunteers
- 20 people
- Sponsor
- Harmony Biosciences Management, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.